Bruce Boliek, MD
Ophthalmology · Raleigh, NCNPI 1033160817
Payments from drug & device makers
Across 134 payments — averaging $39.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$3K
- Biotissue Holdings Inc.$565
- AbbVie$348
- Johnson & Johnson Surgical Vision, Inc.$171
- Tarsus Pharmaceuticals, Inc.$160
- Aerie Pharmaceuticals, Inc.$143
- plus $1K from 20 others
What the payments were for
- Speaking & faculty fees$20%
- Travel & lodging$79115%
- Food & beverage$4,43285%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 35 | $2,698 |
| Biotissue Holdings Inc. | 24 | $565 |
| AbbVie(2 entities) | 11 | $348 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $171 |
| Tarsus Pharmaceuticals, Inc. | 6 | $160 |
| Aerie Pharmaceuticals, Inc. | 5 | $143 |
| Ocular Therapeutix, Inc. | 6 | $142 |
| Rxsight Inc | 1 | $138 |
| Amgen(2 entities) | 7 | $135 |
| Dompe US, Inc. | 4 | $134 |
| Oyster Point Pharma, Inc. | 5 | $97 |
| ANI Pharmaceuticals, Inc. | 4 | $79 |
| Novartis | 3 | $65 |
| Thea Pharma Inc. | 3 | $59 |
| Rayner Intraocular Lenses Limited | 2 | $47 |
| Shire North American Group Inc | 3 | $46 |
| Notal Vision, Inc. | 2 | $33 |
| Sun Pharmaceutical Industries Inc. | 1 | $25 |
| Mallinckrodt Hospital Products Inc. | 1 | $20 |
| Harrow Eye, LLC | 1 | $20 |
| Akorn, Inc. | 1 | $19 |
| Bausch & Lomb Americas Inc. | 1 | $19 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
| Omeros Corporation | 1 | $17 |
| Ivantis, Inc | 1 | $15 |
| Sight Sciences, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LenSx$906
- Rhopressa$234
- Rocklatan$234
- Clareon PanOptix Pro$167
- NGENUITY$149
- Clareon$147
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$138
- SIMBRINZA$134
- AcrySof IQ VIVITY IOL$130
- LUMIGAN$123
- COMBIGAN$123
- Tecnis Simplicity$122
- PanOptix$118
How this compares
$5,226 in reported general payments places this provider in the 75th percentile of 588 ophthalmology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 41 | $47,602 |
| LumiganBimatoprost | 84 | $45,412 |
| XiidraLifitegrast | 16 | $19,794 |
| VyzultaLatanoprostene Bunod | 33 | $17,870 |
| CombiganBrimonidine Tartrate/Timolol | 25 | $13,385 |
| Latanoprost | 504 | $9,452 |
| Alphagan PBrimonidine Tartrate | 28 | $9,126 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 20 | $3,263 |
| Cyclosporine | 14 | $3,212 |
| Brimonidine Tartrate | 148 | $2,228 |
| Timolol Maleate | 130 | $2,088 |
| Prednisolone Acetate | 36 | $1,722 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 35 | $1,167 |
| Dorzolamide Hcl | 45 | $937 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 65 | $762 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $348 | $115,524178 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $19 | $37,66449 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 588 ophthalmology providers in North Carolina.
Other ophthalmology in Raleigh
- Preeya GuptaRaleigh$2M
- Glenn JaffeDurham$38.5M
- Lejla VajzovicDurham$7.5M
- Andrew AntoszykCharlotte$4M
- Majda HadziahmetovicDurham$2.4M
- Thomas WilliamsHickory$1.8M
- James HarrisHickory$1.4M
- Rajiv ShahWinston Salem$1.3M
- Patrick KeltyHickory$1.1M
- Julie WoodwardDurham$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.